Clinical Trial Update: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 clinical trial completed evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous NNC0143-0406 in adults with Type 1 d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• NNC0143-0406

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 1 | Status: COMPLETED